Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoPHOEBE: PI3K inhibition in HER2-overexpressing breast cancer
2012-000738-21Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of buparlisib in breast cancer (2 arms), sponsored by Novartis. Primary endpoint: Pathological complete response rate. Started May 2013; status: completed.
02
Drugs
buparlisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-000738-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000738-21.